Callan JMB Inc. filed a Form 10-Q with the SEC on November 16, 2026, reporting unaudited financial results for the quarterly and nine-month periods ended September 30, 2026, and disclosing an accumulated deficit of $17,441,870 as of that date.
Key Highlights
- Net loss of $7,181,856 for the nine months ended September 30, 2026, compared to a net loss of $5,373,327 for the same period in 2025, according to the filing.
- Revenue of $3,629,167 for the nine months ended September 30, 2026, down from $4,562,604 in the same period of 2025, as reported in the filing.
- ELOC facility transaction expenses totaled $1,453,663 for the nine months ended September 30, 2026, versus $229,041 in the prior-year period.
- Total stockholders' equity fell to $439,161 as of September 30, 2026, from $2,328,039 as of December 31, 2025, the filing disclosed.
- Common shares outstanding of 6,674,718 as of September 30, 2026, up from 4,858,663 as of December 31, 2025, reflecting ELOC share issuances and other stock activity.
- Immaterial revisions to the June 30, 2026 period were disclosed, reducing accumulated deficit by $90,751, as described in Note 11 of the filing.
- A $1,000,000 line of credit appeared as a current liability as of September 30, 2026, with no such balance reported as of December 31, 2025.
Callan JMB Reports Widening Losses and Declining Revenue Through Third Quarter 2026
According to the filing, Callan JMB Inc. (NASDAQ:CJMB) reported a net loss of $2,644,128 for the three months ended September 30, 2026, compared to a net loss of $2,731,341 for the same quarter in 2025. For the nine-month period, the net loss widened to $7,181,856 from $5,373,327 a year earlier. Revenue for the third quarter was $1,146,699, down from $1,446,917 in the third quarter of 2025, and nine-month revenue fell to $3,629,167 from $4,562,604. Gross profit for the nine months was $1,563,597, compared to $1,750,270 in the prior-year period.
The filing disclosed that selling, general and administrative expenses reached $6,902,736 for the nine months ended September 30, 2026, up from $6,274,343 in the same period of 2025. ELOC facility transaction expenses were cited as a significant component of other expenses, totaling $1,453,663 for the nine-month period. Changes in fair value of derivative liability contributed an additional $382,784 in losses for the nine months. The company reported a derivative liability of $754,000 classified as a current liability as of September 30, 2026, compared to $371,216 as a long-term liability as of December 31, 2025.
The filing noted that common shares issued and outstanding increased from 4,858,663 at December 31, 2025, to 6,674,718 at September 30, 2026, primarily through issuances under an Equity Line of Credit (ELOC) arrangement, restricted stock unit vesting, stock-based compensation, and shares issued for professional services. The accumulated deficit grew to $17,441,870 as of September 30, 2026, from $10,260,014 as of December 31, 2025. The filing also indicated that financial statements in the filing reflect the correction of an error to previously issued financial statements, as indicated by the check mark on the cover page.
What Was Disclosed
Callan JMB Inc. filed its quarterly report for the period ended September 30, 2026, disclosing a nine-month net loss of $7,181,856, declining revenue, rising operating expenses, an expanded share count from ELOC issuances, and immaterial revisions to the June 30, 2026 period results.




Please wait processing your request...